Form 8-K ALTEROLA BIOTECH INC. For: May 27
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 27, 2019
Alterola Biotech Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 333-156091 | TBA |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
|
340 S Lemon Ave #4041, Walnut CA |
91789 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 909-584-5853
|
___________________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Section 1 – Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On May 27, 2019, the Company entered into an agreement to acquire Algae Energy Inc. (“Algae Energy”) from Affinity Health and Energy Limited (“AEB”). The agreement was amended in June 2019.
Algae Energy operates an algae production facility in Cumming, Georgia. Under the agreement, the Company shall pay $100,000 in cash as the purchase price for 100% of the shares of AEB.
The Company shall also acquire a license from AEB for algae production technology and intellectual property in North America. Under the agreement, the consideration for this license shall be the forgiveness of an amount equal to the balance of loans owed by AEB to Algae Energy. The balance of these loans is $500,000.
The agreements contains conditions to close, as follows:
- All necessary governmental and third party consents, authorizations and approvals;
- AEB obtaining shareholder approval for the transactions contemplated by the agreement;
- The parties entering into an exclusive sub-license agreement for the algae production technology and intellectual property;
- The parties entering into a standard form royalty agreement in respect of a 20% net royalty payable to AEB in respect of the sale and exploitation of human algae nutraceutical products in North America;
- The parties entering into a standard form royalty agreement in respect of a 2% net royalty payable to AEB on commercial sales and licensing of any new IP developed by Algae Energy post-closing which uses both the algae IP and any cannabis products;
- AEB obtaining a release of the Algae Energy shares from any security holder so the shares may be sold unencumbered;
- The Company and Algae Energy providing to AEB a full and final release on the loans made by Algae Energy to AEB; and
- The Company and Algae Energy providing to AEB a full and final release from any and all obligations relative to the contracts with Reliance Industries in India.
The agreement states that the transactions shall close by August 15, 2019 or a date mutually agreeable to the parties. Upon closing, the current officers and directors of the Company shall resign and nominees of AEB shall be appointed as officers and directors of the Company.
The agreement contains customary representations and warranties of the parties, including, among others, with respect to corporate organization, capitalization, corporate authority, financial statements and compliance with applicable laws. The representations and warranties of each party set forth in the agreement were made solely for the benefit of the other parties to the agreement, and investors are not third-party beneficiaries of the agreement. In addition, such representations and warranties (a) are subject to materiality and other qualifications contained in the agreement, which may differ from what may be viewed as material by investors, (b) were made only as of the date of agreement or such other date as is specified in the agreement and (c) may have been included in the agreement for the purpose of allocating risk between the parties rather than establishing matters as facts. Accordingly, the agreement is included with this filing only to provide investors with information regarding the terms of the agreement, and not to provide investors with any other factual information regarding any of the parties or their respective businesses.
The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the text of such document, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference.
| 2 |
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 21, 2019, the board of directors appointed Irving Aronson, Lalit Kumar, and Dheeraj Jain to our board of directors. In addition, the board appointed Irving Aronson as Chairman of the Board, Lalit Kumar as Chief Executive Officer, Dheeraj Jain as Chief Operating Officer. Peter Maddocks will step down as CEO, however he continues to serve as President, Chief Financial Officer and Corporate Secretary of the company.
Peter E. Maddocks, Chief Financial Officer, Aged 61, is a British Citizen residing in Chatham Kent, England, Peter is a Chartered Accountant who worked for KPMG before he entered the banking world as a financial controller with Citi Bank, ANZ, Abbey National and Grindlays, He spent several years in senior financial controllers position with Citi Bank Private Banking in London, as financial controller of Citi Bank Italy and South East Europe, based in Rome and with Citi Bank Venture Capitals emerging markets group. Over the past fifteen years has held directorships in several private and public companies traded in the USA and has served as Chief Executive officer of a London Stock Exchange “Alternative Investment Market Listed Company in the Mining and Oil and Gas sectors. Over the past twenty years has held directorships in several private and public companies traded in the USA and has served as Chief Executive officer of a London Stock Exchange “Alternative Investment Market Listed Company in the Mining and Oil and Gas sectors. Since 2005 or over the past ten years he has been a President and Chief Executive Officer of Tucumcari Exploration LLC, a Nevada Company engaged in ownership of a Natural Gas project in Tucumcari New Mexico. Since July 28th, 2014 to present date he has been Chairman of London Mining Finance Limited, a privately held company engaged in financing mining ventures. He is also a Director of two privately held property development companies named Regency Homes & Estates Limited and Royal Palace Cove Estates Limited. He is the Chairman of Golden Square Equity Partners Limited and Chairman of London Pharma Holdings Limited. He is He has served as Chief Executive Officer, President, Secretary and Director of Alterola Biotechnology Inc, since March 26th, 2018., he will step down as Chief Executive officer effective immediately, however he will continue to serve as Chief Financial officer, President and corporate secretary of the company.
Irving Aronson Aged 76, is our newly appointed Chairman
Irving Aronson aged 76, is a British citizen residing in London, United Kingdom, he has been Chairman of Millennium Energy Corp, a public company for the past 5 years, since March of 2014. He is originally from South Africa having qualified as a Certified Public Accountant in 1967. He was admitted as a Partner in the Accounting Firm of Schwarz Fine in December 1967. This was the largest South Arica firm of Accountants. The firm merged with Arthur Anderson in March 1980 and Mr. Aronson left the practice in 1981, when he moved to the United Kingdom.
Since 1981, he has carried out private equity and public merger and acquisition transactions for his down account in sectors such as Retail, Hotels, and Natural Resources. He also managed the private family office of leading South African families, who had all been clients of his accounting practice. In 1985, he founded the firm Sellar Morris Properties with Messrs. Irvine Sellar (developer of the Shard Building) and Mel Morris, which became one of the largest property development companies in the United Kingdom. He sold his interest in the firm in 1990.
Mr. Aronson has had extensive interests in the pharmaceutical Fields and assisted in the floatation of Zenith Laboratories Inc. in 1983, which subsequently was acquired by Ivax Inc., one of the largest generic pharmaceutical companies. He is currently the Chairman of Ivory Mint Holdings Corp., a BVI private Investment Company, which invests in the private and public sector in Gold mining, Coal mining and Oil and Gas companies, finances and provides funding and/or merging such companies with quoted public companies and placing equity to provide funding.
He is a graduated with Honors from Cape Town University in 1967.
Lalit Kumar, 40, is our newly appointed Chief Executive Officer, and Director, with immediate effect he was formerly the CEO of Sakthi Automotive Group. He brings several years of executive international experience working in India, Japan, China, Korea and the US. His expertise is in supply chain management and global purchasing at OEMs like GM, Honda and Bombardier. He obtained his MA from Delhi College of Engineering and his MBA from the Institute of Management Technology in Ghaziabad, India. He brings a strong operational, and manufacturing expertise to support the future growth of Alterola Biotech Inc. and he is working on initiatives to expand into the company into Europe, India, and China
Dheeraj Jain, aged 40, is our newly appointed Chief operating Officer and Director, He has previously held the post of Managing Director of Redcliffe Capital, focused on Leverage buyouts, M&A and Property Investments. He is also an active early stage investor and holds a robust portfolio of 35+ businesses mostly in India, Singapore and the USA. He previously held several posts at Nokia including CIO office, Markets Strategy and Global Finance for almost a decade. Before Nokia, he was a management consultant at Zensar Technologies (Fujitsu services JV) for British Gas, UBS, Cisco, amongst others. He is currently a guest lecturer at City University, London. Dheeraj holds a computer science degree from Delhi University, as well as an Executive MBA from Cass Business School, London. He brings a strong financial and operational expertise to the company that will support the future growth of Alterola Biotech Inc. he is based in the United Kingdom and will seek to expand its operations in the U.K., into Europe as well as into India where he has built a reputation as a successful venture capitalist.
Our newly-appointed officers and directors have not had any material direct or indirect interest in any of our transactions or proposed transactions over the last two years. At this time, we do not have any written employment agreements or other formal compensation agreements with any of the officers and directors with the except for Peter E Maddocks who has an employment agreement for $120,000 per year. Compensation arrangements with our new officers and directors are the subject of ongoing discussion and we will make appropriate additional disclosures as they are further developed and formalized.
There are no family relationships between any of the foregoing appointees and any of our directors or executive officers.
| 3 |
Section 9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
| Exhibit No. | Description |
| 2.1 | Share Sale Agreement to acquire Algae Energy Inc., from Affinity Health and Energy Limited |
| 2.2 | Deed of Variation |
| 99.1 | Press Release |
| 4 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alterola Biotech, Inc.
/s/ Peter E. Maddocks
Peter E Maddocks
President and Chief Financial Officer
Date: August, 26, 2019
| 5 |
| Share Sale Agreement |
| Date: May 27th 2019 |
| Parties: |
Alterola Biotech Inc Address:
23 Golden Square, London, W1F 9JP United Kingdom
| |
|
Affinity Energy and Health Limited (ACN 124 544 190) Address:
Unit 2, 100 Railway Road, Subiaco, Perth, Western Australia, Australia
| ||
|
Algae Energy Inc C/0
Unit 2,100 Railway Road, Subiaco, Perth, Western Australia, Australia
|
| Recitals |
|
A. The Vendor is the legal and beneficial owner of 100% of the issued shares in the capital of Company. B.
The Company operates an algae production facility in Cumming, Georgia (Algae Plant), and, following C.
As part of the Purchase, the Vendor will grant to the Purchaser an exclusive licence for the algae D.
The Vendor has agreed to sell, and the Purchaser has agreed to purchase, the Vendor’s Shares
|
| Operative Provisions |
| 1. Definitions and interpretation |
| 1.1 Definitions |
|
In this Agreement: Agreement means the agreement constituted by this document and includes the recitals. Authorisation
means any permit, approval, authorisation, consent, exemption, filing, licence, Business Day means a day that is not a Saturday, Sunday or public holiday in Namibia. Initial
Cash Consideration means USD$100,000 (cash or shares) to be paid to the Vendor in
|
| Share Sale Agreement |
| 1 |
|
Claim
means in relation to any person, a claim, action or proceeding, judgment, damage, loss, cost, Company means Algae Energy Inc. Conditions means the conditions precedent set out in clause 2.1. Confidential
Information means any trade secrets, lists of information pertaining to clients of the Consideration means the Initial Cash Consideration. Contracts
and Agreements means the contracts, agreements and commitments entered into by the Duty
means any stamp, transaction or registration duty or similar charge imposed by any Governmental Encumbrance
means any encumbrance, mortgage, pledge, charge, lien, assignment, hypothecation, End Date means 30 June 2019 or such other date as may be agreed between the Parties in writing. Environmental
Law means any law concerning environmental matters which regulates or affects the Execution Date means the date of this Agreement Governmental
Authority means a government or government department, a governmental or semi- Intellectual
Property means all trademarks, designs, patents and copyrights, whether Australian or Inventory
means all stock (if any) owned by the Company Group and held in connection with the Project Loss
means losses, liabilities, damages, costs, charges and expenses and includes Taxes, Duties and Material
Adverse Effect means any one or series of events whether related or not which individually (a)
when used in a Warranty in relation to the Company, have a material adverse effect on the
|
| Share Sale Agreement |
| 2 |
|
(b)
when used in all other cases in relation to the Company, have a material adverse effect on the (c) affects the Vendor and its ability to comply with its obligations under this Agreement. Algae
Plant Information means and includes the following in the possession or control of the Company
|
|
(a) all IP including surveys, maps, plans and designs; (b) all product samples and information; (c) all assays, reports, scientific information relating to the IP and the Algae Plant; and (d)
all papers, notes, advices and reports extracted or compiled from or based upon the documents
|
| Party means a party to this Agreement and Parties means the parties to this Agreement. |
| Algae Plant Assets means: |
|
(a) the Goodwill; (b) Plant and Equipment; (c) Inventory; (d) Contracts and Agreements; (e) Records; (f) Intellectual Property; (g) Trade and Other Debtors; (h) Creditors, Other Liabilities and Financial Obligations; and (i) all other information which relates to the IP and the Algae Plant. Purchaser
Warranties means the representations and warranties of the Purchaser set out in Schedule Records mean all records of the Company Group. Representative
means, in relation to a party, that party's directors, officers, employees, agents or Settlement
means the settlement on the Settlement Date of the sale and purchase of the Vendor’s Settlement
Date means that date which is 5 Business Days after the satisfaction or waiver of the last Share means a fully paid ordinary share in the capital of the Company.
|
| Share Sale Agreement |
| 3 |
|
Statutes
means all legislation of any country, state or territory enforced at any time, and any rule, Tax
means any tax, levy, charge, impost, duty, fee, deduction, compulsory loan, withholding, stamp, Tax Cost means all costs and expenses incurred in: (a) managing an inquiry; or (b)
conducting any objection, action, defence, or proceeding with the purpose of causing a in relation to Tax or Duty, but does not include the Tax or Duty. Tax Law means any law relating to either Tax or Duty as the context requires. Trade
and Other Debtors means all trade debts and other receivables owed or incurred (but not yet Transaction
means the sale and purchase of the Vendor Shares on the terms and conditions set out in Transaction Document means this Agreement. Transaction Period means the period between the Execution Date and the earlier of: (a) the Settlement Date; and (b) the date this Agreement is terminated. Vendor’s
Shares means 100% of the Shares in the capital of the Company which are beneficially and Vendor’s
Warranties means the Warranties set out in Schedule 1 and Vendor's Warranty means any 1.2 Interpretation In this Agreement unless the context otherwise requires: (a) headings are for convenience only and do not affect its interpretation; (b)
an obligation or liability assumed by, or a right conferred on, 2 or more Parties binds or benefits (c)
the expression person includes an individual, the estate of an individual, a corporation, an (d)
a reference to any party includes that party’s executors, administrators, successors and permitted (e)
a reference to any document (including this Agreement) is to that document as varied, novated,
|
| Share Sale Agreement |
| 4 |
|
(f)
a reference to any statute or to any statutory provision includes any statutory modification or re- (g)
words importing the singular include the plural (and vice versa) and words indicating a gender (h)
reference to parties, clauses, schedules, exhibits or annexures are references to parties, clauses, (i)
where a word or phrase is given a defined meaning, any other part of speech or grammatical form
(j) reference to $ or dollar is to United States currency unless otherwise stated; and
(k) reference to a payment is to a payment by bank cheque unless the recipient otherwise allows.
|
| 2. Conditions Precedent |
| 1.1 Conditions |
| Clauses 3 and 7 of this Agreement do not become binding on the Parties unless and until the following Conditions are satisfied or waived in accordance with this clause: |
|
(a)
the Vendor and/or the Purchaser obtaining all necessary governmental and third-party consents, (b)
the parties entering into an exclusive sub-licence agreement for the algae production technology (c)
the parties entering into a standard form royalty agreement in respect of a 20% net royalty (based
|
| (d) the parties entering into a standard form royalty agreement in respect of a net 2% royalty payable to the Vendor on commercial sales and licensing of any new IP developed by the Company post Completion which uses both the Algae IP and any cannabis products. Such IP will be owned 100% by the Company. |
| 1.2 Benefit of the Conditions |
| (a) The Conditions in clauses 2.1 (a) - (d) are for the mutual benefit of the Purchaser and the Vendor and the Purchaser may, by mutual agreement, on or before the End Date, waive that Condition. |
| 1.3 Best efforts |
| Each Party must provide all reasonable assistance to the others as is necessary to satisfy the Conditions. |
| 1.4 Notice |
| Share Sale Agreement |
| 5 |
| The Purchaser and the Vendors must promptly notify the other in writing if any of the Conditions are satisfied or cannot be satisfied. |
| 1.5 Satisfaction or waiver of Conditions |
| Subject to clause 2.2, if the Conditions set out in clause 2.1 are not satisfied, or waived, by the relevant Party in accordance with the provisions of this Agreement on or before the End Date (as varied or extended), this Agreement shall be deemed to be at an end and of no force or effect with no Party being subject to any of the obligations contained in this Agreement. |
| 3. Transaction |
| 1.6 Agreement to buy and sell Vendor Shares |
| The Vendor, as legal and beneficial owner of the Vendor’s Shares, agrees to sell free from Encumbrances, and the Purchaser agrees to purchase, the Vendor’s Shares for the Consideration and on the further terms and conditions set out in this Agreement. |
| 1.7 Title and Risk |
| Title to and risk in the Vendor's Shares passes to the Purchaser on Settlement. |
| 4. Consideration |
| The Consideration payable by the Purchaser to the Vendors will be satisfied in full by: |
|
(a)
the payment of the Initial Cash Consideration at Settlement; only after receipt of this (b)
an amount equal to the balance of the intercompany loan owing by the Vendor to the
|
| 4.1 Best efforts |
|
Each
Party must provide all reasonable assistance to the others as is necessary to satisfy the Deferred
(a) satisfying the conditions in clause 2.1 above; and
|
| (b) assistance by the Vendor to the Purchaser to agree a schedule of creditors and costs moving forward in order to complete final due diligence and for budgeting purposes moving forward. |
| Acknowledgement and Undertakings |
|
(a)
With effect from Settlement each of the current directors and the company secretary of the (b)
Following Settlement, the Vendor undertakes to provide all reasonable assistance to the
|
| Share Sale Agreement |
| 6 |
|
6. CONDUCT BEFORE SETTLEMENT 6.1 Conduct of Company Group’s Business The
Vendor covenants in favour of the Purchaser that during the period commencing on the Execution
|
|
(a)
dispose of, agree to dispose of, assign, agree to assign, encumber or grant any option over any (b)
grant any option to subscribe for any security in the Company Group or allot or issue or agree to (c) resolve to reduce its share capital in any way; (d) enter into a buy-back agreement or resolve to approve the terms of a buy-back agreement; (e) declare or pay any dividend or make any other distribution of its assets or profits; (f) alter or agree to alter its constitution other than as provided for in this Agreement; or (g) resolve any new programs or budgets other than in the ordinary course of business,
|
| provided that nothing in this clause 7.1 shall prevent the Company Group from running its business in the ordinary course of business. |
| 6.2 Purchaser Access |
|
(a)
The Vendors agree to allow the Purchaser access to the Algae Plant, the Records and other IP (b)
Any information obtained by the Purchaser as a result of such access will be deemed to constitute
|
|
7. Settlement 7.1 Time and Location of Settlement Settlement
shall take place at 9.00am (Perth time) on the Settlement Date at the offices of the Purchaser 7.2 The Vendor’s obligations at Settlement
|
|
At
Settlement, the Vendor must confer on the Purchaser title to the Vendor’s Shares and place the (a)
the Vendor covenants to, deliver or cause to be delivered to the Purchaser in a form and
|
|
(i)
holding statement or share certificate in respect of the Vendor’s Shares, and any other (ii)
separate instruments of transfer in registrable form for the Vendors' Shares in favour of the
|
| Share Sale Agreement |
| 7 |
|
(iii)
the IP and Algae Plant Information and all other information which relates to the Algae (iv)
the common seal (and any duplicate common seal, share seal or official seal) of the (v) all available copies of the constitution of the Company; (vi)
the minute books and other records of meetings or resolutions of members and directors (vii)
all registers of the Company (including the register of members, register of options, register (viii)
all cheque books, financial and accounting books and records, copies of tax returns and
|
|
(b)
procure that a directors’ meeting of the Company is held to attend to the following matters (as (i) % the approval of the registration (subject to payment of stamp duty), if applicable of the transfer
of the Vendor’s Shares and the issue of a new share certificate for the Vendor's (ii)
the transaction of any other reasonable business of which the Purchaser may give notice 7.3 The Purchaser’s obligations at Settlement At
Settlement, the Purchaser must deliver to the Vendors or their nominee Immediately Available Funds 8. Representations and Warranties by the Vendor 8.1 Representations and Warranties The
Vendor gives the Vendor Warranties in favour of the Purchaser, on the Execution Date and on each 8.2 Independent Warranties Each
of the Vendor Warranties is to be construed independently of the others and is not limited by 8.3 Indemnity by Vendor (a)
The Vendor indemnifies and agrees to indemnify the Purchaser and the Company against, and (b)
For the avoidance of doubt, in respect of any breach of Vendor’s Warranty, Loss includes an 8.4 Notification of Warranty Breaches The
Vendor must promptly notify the Purchaser if at any time after the date of this Agreement it becomes Share Sale Agreement
|
| 8 |
|
(a) the Vendor’s Warranty has ceased to be true; or (b)
an act or event has occurred that would or might reasonably be expected to result in the Vendor’s and must also provide the Purchaser with details of that fact. 9. Qualifications and Limitations on Claims 9.1 Limitation Periods The
Vendor is not liable for a breach of a Vendor Warranty unless the Purchaser notifies the Vendor in (a) seven years after Settlement in respect of the Tax Warranties. (b) one year after Settlement in respect of all other Vendor Warranties. 9.2 Meaning of Vendors’Knowledge Where
any Vendor Warranty is qualified by the expression "so far as the Vendor is aware” or “to the (a)
is actually aware of that fact, matter or circumstance on the date the Vendor Warranty is given, (b)
would reasonably be expected to be aware of that fact, matter or circumstance if, on the date the 9.3 Monetary Limit The
maximum aggregate amount which the Purchaser may claim against the Vendors for a breach of a 9.4 Investigation by Purchaser Subject
to clause 12.1, the Vendor Warranties or Claims under any Indemnity or guarantee granted in
|
|
(a)
disclosure and Information made available by the Vendor or the Company to the Purchasers (b)
(b) any information available on public registers in relation to the Company maintained by any All
information relating to the Company Group of which the Purchaser has knowledge (actual or 9.5 Mitigation
|
| The Purchaser must take reasonable action to mitigate all Claims for breach of a Vendor Warranty under this Agreement. |
| 10. Warranties by the Purchaser |
Share Sale Agreement
| 9 |
|
10.1 Purchaser Warranties The
Purchaser gives the Purchaser Warranties in favour of the Vendors on the date of this Agreement 10.2 Independent Warranties Each
of the Purchaser Warranties is to be construed independently of the others and is not limited by
|
| 11. Confidentiality |
| 11.1 Terms to remain confidential |
|
Each
Party is to keep confidential the terms of this Agreement, and any other Confidential Information (a)
to employees, legal advisers, auditors and other consultants requiring the information for the (b) with the consent of the other Parties; (c)
if the information is, at the date of this Agreement, lawfully in the possession of the recipient of (d) if required by law or a stock exchange; (e) if strictly and necessarily required in connection with legal proceedings relating to this Agreement; (f)
if the information is generally and publicly available other than as a result of a breach of (g) to a financier or prospective financier (or its advisers) of a Party. 11.2 Disclosure of Information A
Party disclosing Confidential Information must use all reasonable endeavours to ensure that persons 11.3 Public announcements A
Party may not make any public announcement relating to this Agreement (including the fact that the 11.4 Obligations continuing The
obligations under this clause 15 contain obligations, separate and independent from the other 11.5 Exclusivity
|
| The Vendor agrees that prior to the earlier of the End Date or the date that this Agreement is terminated by the Parties in accordance with the terms of this Agreement, the Vendor must ensure that neither it |
Share Sale Agreement
| 10 |
|
nor
any of its employees, officers, agents, consultants or advisers, except with the prior written consent 12. Dispute Resolution (a)
If a dispute arises in connection with this Agreement, a party to the dispute must give to the other (b)
After the receipt of a Notice of Dispute, the parties to the dispute must negotiate in good faith to (c)
If the dispute is not resolved within 21 days after the Notice of Dispute is given to the other party (d)
If the parties have not agreed upon the mediator and the mediator’s remuneration within 7 days (i) the mediator is the person appointed by; and (ii) the remuneration of the mediator is the amount or rate determined by agreement ]. (e) The parties must pay the mediator’s remuneration in equal shares. (f) Each party must pay its own costs of the mediation. (g)
If the dispute is not resolved within 28 days after the appointment of the mediator (Second Period), 13. Notices 13.1 Notices in writing Each
notice authorised or required to be given to a Party shall be in legible writing and in English 13.2 Initial address of Parties The initial address of the Parties shall be as follows: The Vendor Unit 2, 100 Railway Road, Subiaco, Perth, Western Australia, Australia Email: Attention: The Purchaser: Address: 23 Golden Square, London W1F 9JP, United Kingdom Email: [email protected] Attention: Peter E Maddocks, Chief Executive Officer 14. Non Assignment No Party
may assign any or all of its rights and obligations under this Agreement to any person except
|
| 11 |
|
15. Further Assurance Each
Party shall sign, execute and do all deeds, acts, documents and things as may reasonably be 16. Governing Law This
Agreement shall be governed by and construed in accordance with the law from time to time in the 17. Variation No
modification or alteration of the terms of this Agreement shall be binding unless made in writing dated 18. Costs 18.1 Stamp Duty All stamp duty assessed on or in respect of this Agreement shall be paid 100% by the Purchaser. 18.2 Legal Costs Each
Party shall bear their own legal costs of and incidental to the preparation, negotiation and
|
| EXECUTED by the Parties as an agreement. |
|
Executed by Alterola Biotech Inc Registration number: in accordance with their constituent documents and governing laws: |
| /s/ Peter E Maddocks | /s/ Peter E Maddocks | ||
| Signature of Director | Signature of Director / Company Secretary | ||
| Peter E Maddocks | Peter E Maddocks | ||
| Full Name of Director | Full Name of Director / Company Secretary |
| Share Sale Agreement |
| 12 |
|
Executed by Algae Energy Inc Registration Number in
accordance with their constituent documents and |
| /s/ Malcolm James | /s/ Josh Russell Puckridge | ||
| Signature of Director | Signature of Director / Company Secretary | ||
| MALCOLM JAMES | JOSH RUSSELL PUCKRIDGE | ||
| Full Name of Director | Full Name of Director / Company Secretary |
|
Executed on behalf of AFFINITY ENERGY AND HEALTH LIMITED ACN 124 544190 in accordance with
section 127 of |
| /s/ Malcolm James | /s/ Josh Russell Puckridge | ||
| Signature of Director | Signature of *Director / *Secretary | ||
| MALCOLM JAMES | JOSH RUSSELL PUCKRIDGE | ||
| Full Name of Director | Full Name of *Director / *Secretary | ||
| *delete that which does not apply |
| Share Sale Agreement |
| 13 |
| Schedule 1 - Vendors Warranties |
| Vendors’ warranties |
|
1. Ownership and structure 1.1 Ownership of the Shares (a)
As at the Settlement Date, the Vendor’s Shares will comprise 100% of the issued share capital of (b) The Vendor Shares are fully paid up and have been duly issued and allotted. (c)
The Vendor.is the registered holder and beneficial owner of 100% of the Shares in the Company, (d)
The Vendor is entitled to sell, assign and transfer the full legal and beneficial ownership of the 1.2 Issues of Shares (a)
No person is entitled or has claimed to be entitled, to require the Company Group to issue any (b)
There are no agreements in force under which any person is or may be entitled to, or has the (c)
The Company Group has not given, granted or agreed to grant any option or right (whether 2. Power and Authority 2.1 Power and Capacity The Vendor has full power and authority to enter into and perform its obligations under this Agreement. 2.2 Authorisations The
Vendor has taken all necessary action to authorise the execution, delivery and performance of this 2.3 No Legal Impediment The
entry into and performance of this Agreement and all documents executed pursuant to this |
|
3.
Incorporation
and Corporate Power
(a) So far as the Vendor is aware, the Company: (i)
is duly registered, has full corporate power to own its assets and to carry on its Business (ii)
has done everything necessary to do business lawfully in all jurisdictions in which its
|
| Share Sale Agreement |
| 14 |
| (iii) has conducted the Business in compliance with the constitution of the Company. |
| 4. Material Contracts and Information |
| Copies of any contract, transaction, communication, material information, arrangement or liability to which the Company is a party that involves, or likely to involve, any Material Adverse Effect or obligations or liabilities that, by reason of their nature or magnitude ought reasonably be made known to an intending buyer of the Vendor Shares have been provided and disclosed to the Purchaser. |
| Project Assets - IP and Algae Plant |
| To the best of the Vendor’s knowledge, information and belief, there is no material litigation or proceeding of any nature concerning the Company and its Assets nor are there any issues which do, or potentially do, give rise to a Material Adverse Effect in respect of the Company, the IP and the Algae Plant. |
| Share Sale Agreement |
| 15 |
| Schedule 2 - Purchaser Warranties |
| Purchaser Warranties |
|
1.
The Purchaser has full power and authority to enter into and perform its obligations under this 2.
All necessary authorisations for the execution, delivery and performance by the Purchaser of this 3.
The entry into and performance of this Agreement and all documents executed pursuant to this 4.
The Purchaser is validly incorporated, organised and subsisting in accordance with the laws of its place 5.
The Purchaser enters into and performs this Agreement on its own account and not as trustee for or 6.
This Agreement constitutes a legal, valid and binding obligation on the Purchaser and is enforceable in
|
| Share Sale Agreement |
| 16 |
| Alterola Biotech Inc (Purchaser) |
| And |
|
Affinity Energy
and Health Limited And Algae Energy Inc
|
| DEED OF VARIATION |
| 1 |
| THIS AGREEMENT is made the day of June 2019 |
| BETWEEN |
Alterola Biotech Inc of 23 Golden Square, London, W1F 9JP United Kingdom (Purchaser); AND Affinity
Energy and Health Limited (ACN 124 544 190) of Unit 2, 100 Railway Road, Subiaco Western AND Algae
Energy Inc C/O Unit 2,100 Railway Road, Subiaco, Western Australia, Australia 6008 (collectively referred to as the Parties). |
| RECITALS |
A.
The Purchaser, Vendor and the Company have entered into a Share Sale Agreement B. This Deed of Variation (Deed) is to be read with the Agreement. C. The Parties have agreed to vary Agreement as detailed in this Deed. D.
The Parties agree that the variations contained herein are the only variations to the |
| IT IS AGREED as follows: |
|
1. VARIATIONS a.
The definition of Business Day in the Agreement be amended to mean a day that is not a
b.
The definition of Initial Cash Consideration in the Agreement be amended to mean
|
c.
The definition of End Date in the Agreement be amended to be 15 August 2019 or such d.
The definition of Material Adverse Effect in the Agreement be amended such that the dollar e.
The definition of Algae Plant Assets in the Agreement be amended at clause (f) to read |
| 2 |
| f. That clause 2, Conditions Precedent in the Agreement be deleted in full and replaced with the following: |
2. Conditions Precedent 2.1 Conditions Clauses 3 and 7
of this Agreement do not become binding on the Parties (a)
the Vendor and/or the Purchaser obtaining all necessary governmental (b)
the Vendor obtaining shareholder approval in accordance with the (c)
the parties entering into an exclusive sub-licence agreement for the algae (d)
the parties entering into a standard form royalty agreement in respect of (e)
the parties entering into a standard form royalty agreement in respect of (f)
The Vendor obtaining the release of the Vendor Shares from any security (g)
The Purchaser and the Company providing the Vendor with a full and final (h)
The Purchaser and the Company releasing the Vendor from any and all 2.2 Benefit of the Conditions The
Conditions in clauses 2.1(a), (c), (d), (e) and (f) are for the mutual benefit |
| 3 |
2.3 Best efforts Each
Party must provide all reasonable assistance to the others as is 2.4 Notice The
Purchaser and the Vendor must promptly notify the other in writing if any 2.5 Satisfaction or waiver of Conditions Subject
to clause 2.2, if the Conditions set out in clause 2.1 are not satisfied, or
|
|
g.
That clause 4(a) be amended to delete the words "only after receipt of this payment will this
h. That clause 4 (b) of the Agreement be amended to read 'the payment by the Purchaser to the Vendor
in an amount equal to the balance of the intercompany loan owing by the Vendor to i.
That clause 4.1 of the Agreement be deleted and replaced with "Each Party must provide all (a) satisfying the conditions in clause 2.1 above; and (b)
assistance by the Vendor to the Purchaser to agree a schedule of creditors and j. That clause 7.2(a)(iii) be deleted. k.
That clause 9.3 of the Agreement be deleted and replaced with "The Minimum amount l.
That clause 11 in the Agreement be amended such that references to other clauses are |
|
m.
That clause 12 (c) of the Agreement be amended by deleting "Namibia" at the end of that n.
That clause 13.2 of the Agreement be amended by inserting the initial address of the
|
| 4 |
|
The Vendor Unit 2, 100 Railway
Road, Subiaco Western Australia 6008 Attention: Malcolm James |
|
The Company Unit 2,100 Railway Road, Subiaco, Western Australia 6008 Email: [email protected] Attention: Malcolm James
|
|
2. GENERAL
a. Authority to Execute Each
of the Parties warrants each of the other Parties that they have authority to execute this b. Counterparts This
Agreement may be signed in any number of counterparts which, when taken together, will
|
|
c. Further Assurances Each
Party must promptly do all things (including executing all documents) necessary or desirable d. Variation An
amendment or variation to this Deed is not effective unless it is in writing and signed by the |
|
e. Waiver No
failure or delay on the part of either Party to exercise any right or remedy under this Deed |
|
f. Announcements Neither
Party shall make any press or other public announcement concerning any aspect of this g. Severability If
any provision or part of this Deed is held to be invalid or unenforceable, this Deed shall be |
|
h. Governing Law and Jurisdiction (a) The law of the State of Western Australia governs this Deed (b) the Parties submit to the non-exclusive jurisdiction of the courts of the State of Western Australia and the Federal Court of Australia.
|
| 5 |
| EXECUTED by the Parties as an agreement. |
Executed by Alterola Biotech Inc Registration number: in accordance with their constituent documents and governing laws: |
| Signature of Director | Signature of Director / Company Secretary | ||
| Full Name of Director | Full Name of Director / Company Secretary |
Executed by Algae Energy Inc Registration Number in accordance with their constituent documents and governing laws |
| /s/ Malcolm James | /s/ Josh Russell Puckridge | ||
| Signature of Director | Signature of Director / Company Secretary | ||
| MALCOLM JAMES | JOSH RUSSELL PUCKRIDGE | ||
| Full Name of Director | Full Name of Director / Company Secretary |
Executed on behalf of AFFINITY ENERGY AND HEALTH LIMITED ACN 124 544190 in
accordance with section 127 of |
| /s/ Malcolm James | /s/ Josh Russell Puckridge | ||
| Signature of Director | Signature of *Director / *Secretary | ||
| MALCOLM JAMES | JOSH RUSSELL PUCKRIDGE | ||
| Full Name of Director | Full Name of *Director / * |
||
*delete thatwhich does not apply |
| 6 |
Alterola Biotech Inc, (“ALTA”-OTC MKTS ) announces appointment of a new management team and a definitive agreement to acquire Algae Energy Inc., from Affinity Health and Energy Limited, (“AEB”-AX)
Southfield MI., August 21, 2019 – Alterola Biotech Inc. (“ALTA” OTC MKTS) today announced that it has appointed a new management team and has entered into a definitive purchase agreement to acquire Algae Energy Inc.(AEB) together with its Cumming, Georgia, facility from Affinity Health and Energy Limited.
The transaction will be achieved by the payment and assumption of certain payables of Algae Energy Inc (AEB) and will not require
Alterola Biotech Inc, (ALTA) to issue any new shares of its stock in connection with the acquisition.
Upon closing Algae Energy Inc (AEB) will become a wholly owned subsidiary of Alterola Biotech Inc.,(ALTA) and AEB will continue to carry out research and development work and production of Algae based products for Nutrition, and Animal Feeds, as well as to develop products produced from Hemp derived CBD oils, for Medical, Health, Beverage, and Cosmetics products and will also do research on producing the hybrid products from Algae’s to include CBD, oils.
| 1 |
Alterola is pleased to announce a new and experienced management team, the new officers and Directors appointments are as follows:
Mr. Irving Aronson aged 76, has been appointed as Chairman, of the Board of the company with immediate effect, he is a British citizen residing in London, United Kingdom, has been Chairman of Millennium Energy Corp, an American public company for the past 5 years, he is originally from South Africa having qualified as a Certified Public Accountant in 1967. He was admitted as a Partner in the Accounting Firm of Schwarz Fine in December 1967. This was the largest South Arica firm of Accountants. The firm merged with Arthur Anderson in March 1980 and Mr. Aronson left the practice in 1981, when he moved to the United Kingdom.
Since 1981, he has carried out private equity and public merger and acquisition transactions for his down account in sectors such as Retail, Hotels, and Natural Resources. He also managed the private family office of leading South African families, who had all been clients of his accounting practice. In 1985, he founded the firm Sellar Morris Properties with Messrs. Irvine Sellar (developer of the Shard Building) and Mel Morris, which became one of the largest property development companies in the United Kingdom. He sold his interest in the firm in 1990.
| 2 |
Mr. Aronson has had extensive interests in the pharmaceutical Fields and assisted in the floatation of Zenith Laboratories Inc. in 1983, which subsequently was acquired by Ivax Inc., one of the largest generic pharmaceutical companies. He is currently the Chairman of Ivory Mint Holdings Corp., a BVI private Investment Company, which invests in the private and public sector in Gold mining, Coal mining and Oil and Gas companies, finances and provides funding and/or merging such companies with quoted public companies and placing equity to provide funding.
He is a graduated with Honors from Cape Town University in 1967.
Lalit Verma, aged 40, has been appointed as Chief Executive Officer, with immediate effect he was formerly the CEO of Sakthi Automotive Group. He brings several years of executive international experience working in India, Japan, China, Korea and the US. His expertise is in supply chain management and global purchasing at OEMs like GM, Honda and Bombardier. He obtained his MA from Delhi College of Engineering and his MBA from the Institute of Management Technology in Ghaziabad, India. He brings a strong operational, and manufacturing expertise to support the future growth of Alterola Biotech Inc. and he is working on initiatives to expand into the company into Europe, India, and China
| 3 |
Dheeraj Jain, aged 40, a has been appointed as Chief operating Officer, He has previously held the post of Managing Director of Redcliffe Capital, focused on Leverage buyouts, M&A and Property Investments. He is also an active early stage investor and holds a robust portfolio of 35+ businesses mostly in India, Singapore and the USA. He previously held several posts at Nokia including CIO office, Markets Strategy and Global Finance for almost a decade. Before Nokia, he was a management consultant at Zensar Technologies (Fujitsu services JV) for British Gas, UBS, Cisco, amongst others. He is currently a guest lecturer at City University, London. Dheeraj holds a computer science degree from Delhi University, as well as an Executive MBA from Cass Business School, London. He brings a strong financial and operational expertise to the company that will support the future growth of Alterola Biotech Inc. he is based in the United Kingdom and will seek to expand its operations in the U.K., into Europe as well as into India where he has built a reputation as a successful venture capitalist.
Peter E Maddocks, 61 has stepped down as CEO, however he will remain with the company as a Director, President and Corporate Secretary as well as Chief financial officer.
| 4 |
On completion of the Algae Energy Inc transaction Alterola’s two largest shareholders will be Future Trends Limited, and London Pharma Limited who are both committed to supporting the company’s future growth and expansion plans.
Affinity Health and Energy’s Board of directors has unanimously approved the sale of Algae Energy Inc. to Alterola Biotech
Inc. and is working on obtain the Shareholders approval and Australian Stock Exchange Disclosure and any regulatory approvals as
may be necessary to complete the transaction.
About Algae Energy Inc.
Algae Energy Inc. (AEB). was established in 2011 with the Development and Manufacturing facility in Cumming, Georgia. Algae Energy have developed a proprietary technology for algae growth processes, lighting systems and specialty nutraceutical products. It has a 70,000 SQF modern design, testing and manufacturing facility for cultivation, harvesting and product refinement.
The technology and products can be used for Biofuels, Nutrition, Animal feed, Cannabis products i.e. medical, health, energy, beverage, cosmetics etc. This facility is highly focused on quality control with clean room facility, product packaging, Quality Control laboratory and operated under FDA guidelines for food grade products.
| 5 |
AEB has developed all required technology for Algae based production of Nutraceutical products with strong infrastructure including but not limited to High Efficiency Light Systems, Optimal Nutrient Packages, Photosynthetic Growth Phase, Environmental Climate Control, Water Management Systems, Oil Extraction and Refinement, Sterile Production Environment etc.
Currently AEB is manufacturing and distributing the Alganics via GenCorp Pacific and FeedMealges brand for animal feed and aquaculture market including the R&D work for Reliance Group of India.
AEB has invested up to $30 Million USD into the Georgia facility Located in Cummings Georgia pouring money into R&D and the Manufacturing facility and technology.
With the support of Alterola Biotech as its new parent company of Algae Energy it could become one of the largest highquality development and production facilities in the world for these kinds of products and based on its news business plan to also manufacture CBD, products it projects that it could generate up to $100 Million in revenue with high margins of profitability.
| 6 |
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our filings with the SEC. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Public Relations and Shareholder Information
Lalit Verma, CEO, Tel 248-778-6553
E mail [email protected] Chief Executive Officer, Alterola Biotech Inc
SOURCE: Alterola Biotech Inc.
| 7 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- As Global Fuel Prices Continue Climbing, Investors Worldwide Are Discovering ELEKTROS Inc.'s Vision for Lithium Mining and Advanced EV Patent Technology
- As Rising Fuel Prices Continue Driving Interest in Electric Vehicles, Global Investors Are Increasingly Recognizing ELEKTROS Inc.'s Vision for Lithium Mining and Advanced EV Patent Technology
- Pediatric Occupational Therapy Expert Kathy Schleifer of Pueblo Explains Sensory Integration Therapy for HelloNation
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share